| Literature DB >> 15476623 |
Seung-Woon Rha1, Pramod K Kuchulakanti, Rajbabu Pakala, Edouard Cheneau, Jana A Fournadjiev, Ellen Pinnow, Afework Gebreeyesus, George Aggrey, Zuyue Wang, Augusto D Pichard, Lowell F Satler, Kenneth M Kent, Joseph Lindsay, Ron Waksman.
Abstract
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15476623 DOI： 10.1016/j.amjcard.2004.06.065
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778